Olympiad Research LP Trims Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Olympiad Research LP lowered its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 24.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,715 shares of the company’s stock after selling 3,527 shares during the quarter. Olympiad Research LP’s holdings in Hims & Hers Health were worth $259,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $48,000. GAMMA Investing LLC grew its stake in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares during the period. Finally, Principal Securities Inc. grew its stake in shares of Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after acquiring an additional 1,002 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $49.10 on Monday. The company has a market capitalization of $10.73 billion, a P/E ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a one year low of $9.25 and a one year high of $72.98. The stock has a 50 day moving average price of $35.05 and a 200-day moving average price of $25.83.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,343 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70. Following the sale, the insider now owns 165,254 shares in the company, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 33,513 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at $1,118,296.76. The trade was a 50.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,082,618 shares of company stock worth $37,317,410. Company insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Piper Sandler boosted their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.